Onco-Innovations Announces Closing of Private Placement
Onco-Innovations (OTCQB:ONNVF) has successfully closed its previously announced non-brokered private placement, raising $400,000 through the issuance of 243,903 units at $1.64 per unit. Each unit comprises one common share and one warrant, with warrants exercisable at $2.05 per share until August 13, 2028.
The company will utilize the proceeds for general corporate and working capital purposes, including operational and R&D objectives. Additionally, 2,439 administrative shares were issued to a third party for services related to the placement. All securities are subject to a four-month hold period ending December 14, 2025.
Onco-Innovations (OTCQB:ONNVF) ha completato con successo il collocamento privato non intermediato precedentemente annunciato, raccogliendo $400,000 tramite l'emissione di 243,903 unità a $1.64 per unità. Ciascuna unità comprende una azione ordinaria e un warrant, con i warrant esercitabili a $2.05 per azione fino al 13 agosto 2028.
La società utilizzerà i proventi per scopi aziendali generali e per il capitale circolante, inclusi obiettivi operativi e di R&S. Inoltre, sono state emesse 2,439 azioni amministrative a una terza parte per servizi relativi al collocamento. Tutti i titoli sono soggetti a un periodo di blocco di quattro mesi che termina il 14 dicembre 2025.
Onco-Innovations (OTCQB:ONNVF) ha cerrado con éxito su colocación privada no intermediada anunciada anteriormente, recaudando $400,000 mediante la emisión de 243,903 unidades a $1.64 por unidad. Cada unidad consta de una acción ordinaria y un warrant, siendo los warrants ejercitables a $2.05 por acción hasta el 13 de agosto de 2028.
La compañía utilizará los fondos para fines corporativos generales y capital de trabajo, incluidos objetivos operativos e I+D. Además, se emitieron 2,439 acciones administrativas a un tercero por servicios relacionados con la colocación. Todos los valores están sujetos a un periodo de retención de cuatro meses que finaliza el 14 de diciembre de 2025.
Onco-Innovations (OTCQB:ONNVF)는 이전에 공지한 중개인 없이 진행된 사모 발행을 성공적으로 마감하여 243,903단위를 단위당 $1.64에 발행해 $400,000를 조달했습니다. 각 단위는 보통주 1주와 워런트 1개로 구성되며, 워런트는 주당 $2.05에 2028년 8월 13일까지 행사할 수 있습니다.
회사는 조달 자금을 운영 및 연구개발을 포함한 일반 법인 목적과 운전자본으로 사용할 예정입니다. 또한 발행 관련 서비스에 대해 제3자에게 2,439주의 관리주식을 발행했습니다. 모든 증권에는 2025년 12월 14일에 종료되는 4개월간의 보호예수 기간이 적용됩니다.
Onco-Innovations (OTCQB:ONNVF) a clôturé avec succès son placement privé non-intermédiaire précédemment annoncé, levant 400 000 $ par l'émission de 243 903 unités à 1,64 $ par unité. Chaque unité comprend une action ordinaire et un warrant, les warrants étant exerçables à 2,05 $ par action jusqu'au 13 août 2028.
La société utilisera les fonds pour des besoins généraux de l'entreprise et le fonds de roulement, y compris des objectifs opérationnels et de R&D. De plus, 2 439 actions administratives ont été émises à un tiers pour des services liés au placement. Tous les titres sont soumis à une période de blocage de quatre mois prenant fin le 14 décembre 2025.
Onco-Innovations (OTCQB:ONNVF) hat die zuvor angekündigte, ohne Makler durchgeführte Privatplatzierung erfolgreich abgeschlossen und dabei $400.000 durch die Ausgabe von 243.903 Einheiten zu je $1,64 pro Einheit eingenommen. Jede Einheit besteht aus einer Stammaktie und einem Warrant; die Warrants sind zum Preis von $2,05 pro Aktie bis zum 13. August 2028 ausübbar.
Die Gesellschaft verwendet die Mittel für allgemeine Unternehmenszwecke und zur Deckung des Umlaufvermögens, einschließlich operativer Ziele und F&E. Zusätzlich wurden einem Dritten zur Vergütung für mit der Platzierung verbundene Leistungen 2.439 Verwaltungsaktien ausgegeben. Alle Wertpapiere unterliegen einer viermonatigen Haltefrist, die am 14. Dezember 2025 endet.
- None.
- Potential dilution to existing shareholders
- Small offering size may indicate limited investor interest
Not for distribution to United States wire services or for dissemination in the United States
VANCOUVER, BC / ACCESS Newswire / August 13, 2025 / Onco-Innovations Limited (CBOE CA:ONCO)(Frankfurt:W1H, WKN:A3EKSZ)(OTCQB:ONNVF) ("Onco" or the "Company") is pleased to announce that it has closed its previously-announced (see news release dated July 29, 2025) non-brokered private placement (the "Private Placement") of 243,903 units of the Company (the "Units") at a price of
The proceeds from the Private Placement will be used for general corporate and working capital purposes, including in pursuit of the Company's operational and research and development objectives.
The Company has also issued 2,439 Shares ("Administrative Shares") of the Company to an arm's-length third party, in consideration for administrative services rendered in connection with the Private Placement.
Pursuant to applicable securities laws, all securities issued under the Private Placement and the Administrative Shares will be subject to a statutory hold period of four months and one day, expiring on December 14, 2025.
The securities described herein have not been and will not be registered under the United States Securities Act of 1933, as amended, or any U.S. state securities laws, and may not be offered or sold in the United States absent registration or available exemptions from such registration requirements. This press release does not constitute an offer to sell or a solicitation of an offer to buy any securities in the United States, or in any jurisdiction in which such offer, solicitation or sale would be unlawful.
About Onco-Innovations Limited
Onco-Innovations is a Canadian-based company dedicated to cancer research and treatment, specializing in oncology. Onco's mission is to pursue the prevention and treatment of cancer through pioneering research and innovative solutions. The company has secured an exclusive worldwide license to patented technology that targets solid tumours.
ON BEHALF OF ONCO-INNOVATIONS LIMITED,
"Thomas O'Shaughnessy"
Chief Executive Officer
For more information, please contact:
Thomas O'Shaughnessy
Chief Executive Officer
Tel: + 1 888 261 8055
investors@oncoinnovations.com
Forward-Looking Statements Caution. This news release contains forward-looking statements, including in relation to the Private Placement generally, and the anticipated closing date, use of proceeds and anticipated proceeds thereof, as well as to the Company's business and plans generally, and other statements that are not historical facts. Forward-looking statements are often identified by terms such as "will", "may", "potential", "should", "anticipate", "expects" and similar expressions. All statements other than statements of historical fact, included in this release are forward-looking statements that involve risks and uncertainties. There can be no assurance that such statements will prove to be accurate and actual results and future events could differ materially from those anticipated in such statements. Important factors that could cause actual results to differ materially from the Company's expectations include the failure to complete the Private Placement as contemplated, or at all, that the anticipated proceeds may be far lower than expected, that the proceeds therefrom may be used other than as currently contemplated, the failure to receive regulatory approval in respect of the Private Placement, and other risks detailed from time to time in the filings made by the Company with securities regulators. The reader is cautioned that assumptions used in the preparation of any forward-looking information may prove to be incorrect. Events or circumstances may cause actual results to differ materially from those predicted, as a result of numerous known and unknown risks, uncertainties, and other factors, many of which are beyond the control of the Company. The reader is cautioned not to place undue reliance on any forward-looking information. Such information, although considered reasonable by management at the time of preparation, may prove to be incorrect and actual results may differ materially from those anticipated. Forward-looking statements contained in this news release are expressly qualified by this cautionary statement. The forward-looking statements contained in this news release are made as of the date of this news release and the Company will update or revise publicly any of the included forward-looking statements as expressly required by applicable law.
SOURCE: Onco-Innovations Limited
View the original press release on ACCESS Newswire
FAQ
How much did Onco-Innovations (ONNVF) raise in its August 2025 private placement?
What are the terms of ONNVF's August 2025 private placement warrants?
When does the hold period expire for Onco-Innovations' August 2025 private placement securities?
How will Onco-Innovations use the proceeds from its August 2025 private placement?
